Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: M...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature communications Ročník 14; číslo 1; s. 4444 - 10
Hlavní autori:	Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 24.07.2023 Nature Publishing Group Nature Portfolio
Predmet:	13/95 38/23 631/67/1059/153 692/308/153 692/4028/67/1347 Administration, Oral Anticancer properties Antitumor agents Biopsy Breast cancer Cancer therapies Cyclin-dependent kinase 4 Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinases Diarrhea Disease control DNA-directed RNA polymerase Enzyme Inhibitors ErbB-2 protein Fulvestrant Humanities and Social Sciences Humans Inhibitors Lymphocytes Malignancy Modules multidisciplinary Oral administration Patients Pharmacodynamics Pharmacokinetics RNA polymerase RNA polymerase II Safety Science Science (multidisciplinary) Solid tumors Substrates Triple Negative Breast Neoplasms Tumors Vomiting
ISSN:	2041-1723, 2041-1723
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!